HealthEquity Research and Development Expenses 2014-2024 | HQY
HealthEquity annual/quarterly research and development expenses history and growth rate from 2014 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
- HealthEquity research and development expenses for the quarter ending January 31, 2024 were $0.055B, a 4.77% increase year-over-year.
- HealthEquity research and development expenses for the twelve months ending January 31, 2024 were $0.219B, a 13.15% increase year-over-year.
- HealthEquity annual research and development expenses for 2024 were $0.219B, a 13.15% increase from 2023.
- HealthEquity annual research and development expenses for 2023 were $0.193B, a 22.88% increase from 2022.
- HealthEquity annual research and development expenses for 2022 were $0.157B, a 26.08% increase from 2021.
| HealthEquity Annual Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2024 | $219 |
| 2023 | $193 |
| 2022 | $157 |
| 2021 | $125 |
| 2020 | $78 |
| 2019 | $35 |
| 2018 | $27 |
| 2017 | $22 |
| 2016 | $17 |
| 2015 | $11 |
| 2014 | $7 |
| 2013 | $4 |
| HealthEquity Quarterly Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2024-01-31 | $55 |
| 2023-10-31 | $56 |
| 2023-07-31 | $55 |
| 2023-04-30 | $53 |
| 2023-01-31 | $53 |
| 2022-10-31 | $49 |
| 2022-07-31 | $47 |
| 2022-04-30 | $45 |
| 2022-01-31 | $46 |
| 2021-10-31 | $38 |
| 2021-07-31 | $38 |
| 2021-04-30 | $35 |
| 2021-01-31 | $32 |
| 2020-10-31 | $31 |
| 2020-07-31 | $31 |
| 2020-04-30 | $31 |
| 2020-01-31 | $32 |
| 2019-10-31 | $24 |
| 2019-07-31 | $12 |
| 2019-04-30 | $11 |
| 2019-01-31 | $10 |
| 2018-10-31 | $9 |
| 2018-07-31 | $8 |
| 2018-04-30 | $8 |
| 2018-01-31 | $7 |
| 2017-10-31 | $7 |
| 2017-07-31 | $7 |
| 2017-04-30 | $6 |
| 2017-01-31 | $7 |
| 2016-10-31 | $6 |
| 2016-07-31 | $5 |
| 2016-04-30 | $5 |
| 2016-01-31 | $5 |
| 2015-10-31 | $4 |
| 2015-07-31 | $4 |
| 2015-04-30 | $4 |
| 2015-01-31 | $3 |
| 2014-10-31 | $3 |
| 2014-07-31 | $2 |
| 2014-04-30 | $2 |
| 2014-01-31 | |
| 2013-10-31 | $2 |
| 2013-07-31 | $2 |
| 2013-01-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $6.886B | $1.000B |
| HealthEquity provides integrated solutions for health-care account management, health reimbursement arrangement and flexible spending accounts for health plans, insurance companies and third-party administrators in the United States. HealthEquity's flagship health savings account or HSA is a financial account through which consumers spend and save for the long term for healthcare on a tax-advantaged basis. This has provided the company with a competitive edge in the MedTech industry. Other than HSAs, the company offers Healthcare saving and spending platform, Investment platform and advisory services and Reimbursement arrangements. In addition, HealthEquity offers health reimbursement and flexible spending arrangements solutions; Employee Retirement Income Security Act's plan administration and investment services. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $124.869B | 15.67 |
| Cencora (COR) | United States | $48.051B | 19.18 |
| ICON (ICLR) | Ireland | $25.434B | 24.01 |
| DiDi Global (DIDIY) | China | $24.400B | 0.00 |
| Avantor (AVTR) | United States | $16.238B | 23.94 |
| Viatris (VTRS) | United States | $13.880B | 3.96 |
| CochLear (CHEOY) | $13.776B | 0.00 | |
| Revvity (RVTY) | United States | $12.539B | 21.83 |
| Medpace Holdings (MEDP) | United States | $12.267B | 40.36 |
| Charles River Laboratories (CRL) | United States | $11.798B | 21.50 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $11.548B | 0.00 |
| Natera (NTRA) | United States | $11.205B | 0.00 |
| Solventum (SOLV) | United States | $11.115B | 0.00 |
| Sonic Healthcare (SKHHY) | Australia | $8.282B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $7.290B | 37.01 |
| Bausch + Lomb (BLCO) | Canada | $5.197B | 19.99 |
| Organon (OGN) | United States | $4.771B | 4.59 |
| Doximity (DOCS) | United States | $4.444B | 33.08 |
| PACS (PACS) | United States | $3.713B | 0.00 |
| Sotera Health (SHC) | United States | $3.227B | 15.83 |
| Surgery Partners (SGRY) | United States | $3.120B | 28.88 |
| Progyny (PGNY) | United States | $3.079B | 51.68 |
| GoodRx Holdings (GDRX) | United States | $2.840B | 143.80 |
| Life Times (LTH) | United States | $2.783B | 30.76 |
| Premier (PINC) | United States | $2.511B | 9.19 |
| Teladoc Health (TDOC) | United States | $2.203B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $2.164B | 7.00 |
| Agilon Health (AGL) | United States | $2.055B | 0.00 |
| BrightSpring Health Services (BTSG) | United States | $1.811B | 0.00 |
| Agiliti (AGTI) | United States | $1.368B | 22.33 |
| NovoCure (NVCR) | Jersey | $1.360B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.331B | 0.00 | |
| Alignment Healthcare (ALHC) | United States | $0.985B | 0.00 |
| Pediatrix Medical (MD) | United States | $0.760B | 7.86 |
| Embecta (EMBC) | United States | $0.594B | 3.92 |
| InnovAge Holding (INNV) | United States | $0.531B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.522B | 0.00 |
| Enhabit (EHAB) | United States | $0.503B | 45.59 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.492B | 0.00 |
| LifeMD (LFMD) | United States | $0.482B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.434B | 0.00 |
| Beauty Health (SKIN) | United States | $0.400B | 0.00 |
| CareDx (CDNA) | United States | $0.391B | 0.00 |
| DocGo (DCGO) | United States | $0.376B | 60.17 |
| MultiPlan (MPLN) | United States | $0.371B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.349B | 0.00 |
| ModivCare (MODV) | United States | $0.335B | 4.44 |
| Sharecare (SHCR) | United States | $0.290B | 0.00 |
| GeneDx Holdings (WGS) | United States | $0.289B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.269B | 0.00 |
| Biodesix (BDSX) | United States | $0.142B | 0.00 |
| So-Young (SY) | China | $0.125B | 41.83 |
| Oncology Institute (TOI) | United States | $0.085B | 0.00 |
| Pono Capital Two (PTWO) | United States | $0.078B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.055B | 0.00 |
| NeueHealth (NEUE) | United States | $0.050B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.035B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.033B | 0.00 |
| Nutex Health (NUTX) | United States | $0.033B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.030B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.029B | 0.00 |
| DermTech (DMTK) | United States | $0.021B | 0.00 |
| OncoCyte (OCX) | United States | $0.021B | 0.00 |
| BIMI Holdings (BIMI) | United States | $0.014B | 0.00 |
| Aesthetic Medical Hldngs Group (AIH) | China | $0.013B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.011B | 0.00 | |
| TRxADE HEALTH (MEDS) | United States | $0.009B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.008B | 0.00 |
| XWELL (XWEL) | United States | $0.008B | 0.00 |
| NewGenIvf Group (NIVF) | Singapore | $0.007B | 0.00 |
| OpGen (OPGN) | United States | $0.007B | 0.00 |
| Assure Holdings (IONM) | United States | $0.005B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |